Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: A randomized controlled trial

Intensive Care Medicine

Volumn 38, Issue 7, 2012, Pages 1118-1125

  Van Delden, Christian ^a,b   Köhler, Thilo ^a,b   Brunner Ferber, Françoise ^c   François, Bruno ^d   Carlet, Jean ^e   Pechère, Jean Claude ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Brunner Naga ^*  (Switzerland)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e SAINT JOSEPH HOSPITAL   (France)

Author keywords

Pseudomonas aeruginosa; Quorum sensing; Rhamnolipids; Ventilator associated pneumonia; Virulence

Indexed keywords

AZITHROMYCIN; RHAMNOLIPID;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL VIRULENCE; BRADYCARDIA; BRONCHOSPASM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PILOT STUDY; PSEUDOMONAS PNEUMONIA; QUORUM SENSING; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; GLYCOLIPIDS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; VIRULENCE;

EID: 84862641805     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-012-2559-3     Document Type: Article

References (26)

1. C Van Delden BH Iglewski 1998 Cell-to-cell signaling and Pseudomonas aeruginosa infections Emerg Infect Dis 4 551 9866731 10.3201/eid0404.980405
2. RS Smith BH Iglewski 2003 Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target J Clin Invest 112 1460 1465 14617745 1:CAS:528:DC%2BD3sXptFWqt7w%3D
3. TB Rasmussen M Givskov 2006 Quorum sensing inhibitors: a bargain of effects Microbiology 152 895 904 16549654 10.1099/mic.0.28601-0 1:CAS:528:DC%2BD28XjslyktLk%3D
4. J Chastre JY Fagon 2002 Ventilator-associated pneumonia Am J Respir Crit Care Med 165 867 11934711
5. A Torres S Ewig H Lode J Carlet 2009 Defining, treating and preventing hospital acquired pneumonia: European perspective Intensive Care Med 35 9 29 18989656 10.1007/s00134-008-1336-9
6. M Nguile-Makao JR Zahar A Francais A Tabah M Garrouste-Orgeas B Allaouchiche D Goldgran-Toledano E Azoulay C Adrie S Jamali C Clec'h B Souweine JF Timsit 2010 Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models Intensive Care Med 36 781 789 20232046 10.1007/s00134-010-1824-6
7. RE Hancock DP Speert 2000 Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment Drug Resist Updat 3 247 255 11498392 10.1054/drup.2000.0152 1:CAS:528:DC%2BD3cXnt12rsL8%3D
8. N Mesaros P Nordmann P Plesiat M Roussel-Delvallez J Van Eldere Y Glupczynski Y Van Laethem F Jacobs P Lebecque A Malfroot PM Tulkens F Van Bambeke 2007 Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 13 560 578 1:CAS:528:DC%2BD2sXms1Oksbs%3D
9. C van Delden 2007 Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 30 Suppl 1 S71 S75 17698326 10.1016/j.ijantimicag.2007.06.015
10. van Delden C (2004) Virulence factors in Pseudomonas aeruginosa. In: Ramos JL (ed) The Pseudomonads. Kluwer Academic, New York, pp 3-46
11. K Tateda R Comte JC Pechère T Köhler K Yamaguchi C Van Delden 2001 Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother 45 1930 1933 11353657 10.1128/AAC.45.6.1930-1933.2001 1:CAS:528:DC%2BD3MXjslyqt7Y%3D
12. S Favre-Bonté T Köhler C Van Delden 2003 Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin J Antimicrob Chemother 52 598 604 12951348 10.1093/jac/dkg397
13. Y Nalca L Jansch F Bredenbruch R Geffers J Buer S Haussler 2006 Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach Antimicrob Agents Chemother 50 1680 1688 16641435 10.1128/AAC.50.5.1680-1688.2006 1:CAS:528:DC%2BD28XksVKkt74%3D
14. N Hoffmann B Lee M Hentzer TB Rasmussen Z Song HK Johansen M Givskov N Hoiby 2007 Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice Antimicrob Agents Chemother 51 3677 3687 17620382 10.1128/AAC.01011-06 1:CAS:528:DC%2BD2sXhtFGhtbnP
15. T Kohler GG Perron A Buckling C van Delden 2010 Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa PLoS Pathog 6 e1000883 20463812 10.1371/journal.ppat.1000883
16. DR Baldwin R Wise JM Andrews JP Ashby D Honeybourne 1990 Azithromycin concentrations at the sites of pulmonary infection Eur Respir J Off J Eur Soc Clin Respir Physiol 3 886 890 1:STN:280:DyaK3M7ltlCktA%3D%3D
17. J Pugin R Auckenthaler N Mili JP Janssens PD Lew PM Suter 1991 Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid Am Rev Respir Dis 143 1121 2024824 1:STN:280:DyaK3M3itFektQ%3D%3D
18. N Singh P Rogers CW Atwood MM Wagener VL Yu 2000 Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription Am J Respir Crit Care Med 162 505 511 10934078 1:STN:280:DC%2BD3cvjtlChsg%3D%3D
19. T Kohler A Buckling C van Delden 2009 Cooperation and virulence of clinical Pseudomonas aeruginosa populations Proc Natl Acad Sci USA 106 6339 6344 19332772 10.1073/pnas.0811741106 1:CAS:528:DC%2BD1MXlsFars7g%3D
20. T Kohler R Guanella J Carlet C van Delden 2010 Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients Thorax 65 703 710 20685744 10.1136/thx.2009. 133082
21. T Kohler V Donner C van Delden 2010 Lipopolysaccharide as shield and receptor for R-pyocin-mediated killing in Pseudomonas aeruginosa J Bacteriol 192 1921 1928 20118263 10.1128/JB.01459-09 1:CAS:528:DC%2BC3cXksVOhs7o%3D
22. AR Hauser E Cobb M Bodi D Mariscal J Valles JN Engel J Rello 2002 Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa Crit Care Med 30 521 11990909 10.1097/00003246-200203000-00005 1:CAS:528:DC%2BD38XislSmsrw%3D
23. G Singh B Wu MS Baek A Camargo A Nguyen NA Slusher R Srinivasan JP Wiener-Kronish SV Lynch 2010 Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration Microb Pathog 49 196 203 20570614 10.1016/j.micpath.2010.05.013 1:CAS:528: DC%2BC3cXpvVKitbY%3D
24. S Bleves C Soscia P Nogueira-Orlandi A Lazdunski A Filloux 2005 Quorum sensing negatively controls type III secretion regulon expression in Pseudomonas aeruginosa PAO1 J Bacteriol 187 3898 3902 15901720 10.1128/JB.187.11.3898-3902. 2005 1:CAS:528:DC%2BD2MXks12nurk%3D
25. Tamaoki J, Kadota J, Takizawa H (2004) Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117 Suppl 9A:5S-11S
26. GW Amsden 2005 Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55 10 21 15590715 10.1093/jac/dkh519 1:CAS:528:DC%2BD2MXkt1aisg%3D%3D